JP2017510552A - 線維性疾患を治療するための方法 - Google Patents

線維性疾患を治療するための方法 Download PDF

Info

Publication number
JP2017510552A
JP2017510552A JP2016550760A JP2016550760A JP2017510552A JP 2017510552 A JP2017510552 A JP 2017510552A JP 2016550760 A JP2016550760 A JP 2016550760A JP 2016550760 A JP2016550760 A JP 2016550760A JP 2017510552 A JP2017510552 A JP 2017510552A
Authority
JP
Japan
Prior art keywords
regulator
combination
translation
fibrosis
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510552A5 (enExample
Inventor
ジェイムズ アップルマン，
ジェイムズ アップルマン，
ペギー エー． トンプソン，
ペギー エー． トンプソン，
Original Assignee
イーフェクター セラピューティクス， インコーポレイテッド
イーフェクター セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーフェクター セラピューティクス， インコーポレイテッド, イーフェクター セラピューティクス， インコーポレイテッド filed Critical イーフェクター セラピューティクス， インコーポレイテッド
Publication of JP2017510552A publication Critical patent/JP2017510552A/ja
Publication of JP2017510552A5 publication Critical patent/JP2017510552A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
JP2016550760A 2014-02-07 2015-02-07 線維性疾患を治療するための方法 Pending JP2017510552A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461937272P 2014-02-07 2014-02-07
US61/937,272 2014-02-07
US201462010004P 2014-06-10 2014-06-10
US62/010,004 2014-06-10
US201462037497P 2014-08-14 2014-08-14
US62/037,497 2014-08-14
PCT/US2015/014939 WO2015120350A2 (en) 2014-02-07 2015-02-07 Compositions and methods for treating fibrotic disease

Publications (2)

Publication Number Publication Date
JP2017510552A true JP2017510552A (ja) 2017-04-13
JP2017510552A5 JP2017510552A5 (enExample) 2018-03-22

Family

ID=52684645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550760A Pending JP2017510552A (ja) 2014-02-07 2015-02-07 線維性疾患を治療するための方法

Country Status (7)

Country Link
US (2) US9993494B2 (enExample)
EP (1) EP3102703A2 (enExample)
JP (1) JP2017510552A (enExample)
CN (1) CN106102775A (enExample)
AU (1) AU2015213721B2 (enExample)
CA (1) CA2938592A1 (enExample)
WO (1) WO2015120350A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521750A (ja) * 2017-05-24 2020-07-27 イーフェクター セラピューティクス， インコーポレイテッド 抗腫瘍免疫応答を改善するための組成物および方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US11026945B2 (en) * 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
CN109982693A (zh) 2016-09-22 2019-07-05 香港大学 细胞异常分化和isr相关疾病的预防和治疗方法
WO2018149978A1 (en) * 2017-02-16 2018-08-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
CN106983738B (zh) * 2017-04-13 2020-03-10 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用
CN107260730B (zh) * 2017-05-31 2019-10-22 上海市东方医院 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途
FI3658141T3 (fi) 2017-07-24 2023-03-02 Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella
SG11201913541QA (en) 2017-07-28 2020-02-27 Kyorin Pharmaceutical Co Ltd Therapeutic agent for fibrosis
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
CN107916254B (zh) * 2017-11-29 2020-05-12 武汉大学 Homer1单克隆抗体及其应用
CN108192984B (zh) * 2018-02-13 2020-06-23 浙江大学 与湖羊肉质性状相关的分子标记及特异性引物对和应用
WO2019180664A1 (en) * 2018-03-21 2019-09-26 The University Of Hong Kong Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
KR20220061945A (ko) 2019-07-02 2022-05-13 이펙터 테라퓨틱스, 인크. Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물
KR102100163B1 (ko) * 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
CN111228464A (zh) * 2020-02-28 2020-06-05 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 广谱抗冠状病毒的多肽及其用途
CN113679841A (zh) * 2020-05-19 2021-11-23 上海市同济医院 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用
US11304947B2 (en) 2020-05-22 2022-04-19 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
TW202210069A (zh) * 2020-05-29 2022-03-16 美商諾沃麥迪斯有限責任公司 聯芳磺胺類及其醫藥組合物與彼等用於治療纖維化肺疾病之用途
EP4217378A4 (en) * 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
CA3207882A1 (en) * 2021-01-15 2022-07-21 Children's Hospital Medical Center Methods for optimizing cftr-modulator therapy
GB202109534D0 (en) * 2021-07-01 2021-08-18 Anglia Ruskin Univ Higher Education Corporation Treatment of scarring
KR20240041963A (ko) * 2021-07-22 2024-04-01 상하이 신비다 바이오테크놀로지 컴퍼니 리미티드 섬유성 질환을 완화 또는 치료하는 약학 조성물 또는 약제학적 키트 및 이의 용도
WO2023114969A2 (en) * 2021-12-17 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment of lung conditions with integrin subunit alpha 1 (itga1) inhibitors
CN115558712A (zh) * 2022-09-22 2023-01-03 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
CN119925378A (zh) * 2023-11-03 2025-05-06 成都嘉葆药银医药科技有限公司 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用
CN117589999A (zh) * 2023-11-17 2024-02-23 深圳市人民医院 Pfkp作为慢性肾脏疾病治疗靶点的应用及其抑制剂
CN120789266A (zh) * 2025-09-10 2025-10-17 山东第一医科大学第一附属医院(山东省千佛山医院) Eif3a抑制剂在制备治疗肝纤维化药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
JP4512828B2 (ja) * 2005-04-12 2010-07-28 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
GB0617117D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of diagnosis
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
US7550300B1 (en) * 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
EP2358913B1 (en) 2008-11-03 2017-03-22 The Regents of The University of California Methods for detecting modification resistant nucleic acids
EP2373311A1 (en) 2008-12-05 2011-10-12 InterMed Discovery GmbH Inhibitors of hif-1 protein accumulation
US20100152531A1 (en) * 2008-12-11 2010-06-17 Paracor Medical, Inc. Implantable medical device for drug delivery and method of use
WO2010080248A2 (en) 2008-12-18 2010-07-15 The Board Of Regents Of The University Of Texas System Peptides that bind eukaryotic translation initiation factor 4e
WO2011054893A2 (en) * 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof
AU2011276539A1 (en) 2010-06-28 2013-02-07 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
EP2925718B1 (en) 2012-11-30 2018-08-01 Novomedix, LLC Substituted biaryl sulfonamides and the use thereof
CN105074462B (zh) 2013-02-07 2019-08-23 加利福尼亚大学董事会 翻译谱分析在鉴定用于治疗性处理的靶标分子中的应用
US9956226B2 (en) 2013-02-11 2018-05-01 President And Fellows Of Harvard College Methods and compounds for the inhibition of cellular proliferation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J CELL PHYSIOL., vol. 226, no. 11, JPN6018043786, 2011, pages 3004 - 3013, ISSN: 0004214004 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521750A (ja) * 2017-05-24 2020-07-27 イーフェクター セラピューティクス， インコーポレイテッド 抗腫瘍免疫応答を改善するための組成物および方法
JP7158416B2 (ja) 2017-05-24 2022-10-21 イーフェクター セラピューティクス， インコーポレイテッド 抗腫瘍免疫応答を改善するための組成物および方法

Also Published As

Publication number Publication date
CN106102775A (zh) 2016-11-09
US20150224132A1 (en) 2015-08-13
US20190038657A1 (en) 2019-02-07
US10576098B2 (en) 2020-03-03
US9993494B2 (en) 2018-06-12
WO2015120350A3 (en) 2015-10-01
AU2015213721A1 (en) 2016-07-28
AU2015213721B2 (en) 2021-05-20
WO2015120350A2 (en) 2015-08-13
CA2938592A1 (en) 2015-08-13
EP3102703A2 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
JP2017510552A (ja) 線維性疾患を治療するための方法
Zhang et al. SQSTM1-dependent autophagic degradation of PKM2 inhibits the production of mature IL1B/IL-1β and contributes to LIPUS-mediated anti-inflammatory effect
Zhang et al. WNT signaling underlies the pathogenesis of neuropathic pain in rodents
Lu et al. Targeting WWP1 ameliorates cardiac ischemic injury by suppressing KLF15-ubiquitination mediated myocardial inflammation
EP4291239A2 (en) Compounds, compositions and methods for treating age-related diseases and conditions
Lin et al. Ellagic acid inhibits proliferation and migration of cardiac fibroblasts by down-regulating expression of HDAC1
Peretti et al. TrkB signaling regulates the cold-shock protein RBM3-mediated neuroprotection
Li et al. Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats
Wang et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation
Slaats et al. Nephronophthisis: should we target cysts or fibrosis?
Fang et al. FUNDC1/PFKP-mediated mitophagy induced by KD025 ameliorates cartilage degeneration in osteoarthritis
Zhu et al. Down‐regulation of Rac GTPase‐activating protein OCRL1 causes aberrant activation of Rac1 in osteoarthritis development
Liao et al. Acteoside alleviates blood–brain barrier damage induced by ischemic stroke through inhibiting microglia HMGB1/TLR4/NLRP3 signaling
WO2020095971A1 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
Cao et al. WNT10A induces apoptosis of senescent synovial resident stem cells through Wnt/calcium pathway-mediated HDAC5 phosphorylation in OA joints
Ma et al. Phillyrin: a potential therapeutic agent for osteoarthritis via modulation of NF-κB and Nrf2 signaling pathways
Alenchery et al. PAI‐1 mediates TGF‐β1‐induced myofibroblast activation in tenocytes via mTOR signaling
Zhu et al. TNKS1BP1 mediates AECII senescence and radiation induced lung injury through suppressing EEF2 degradation
US20210353681A1 (en) Use of tnks inhibitors for regeneration of cartilage
Chen et al. Acacetin Suppresses IL‐1β‐Induced Expression of Matrix Metalloproteinases in Chondrocytes and Protects against Osteoarthritis in a Mouse Model by Inhibiting NF‐κB Signaling Pathways
Yu et al. Myo1b promotes premature endothelial senescence and dysfunction via suppressing autophagy: implications for vascular aging
Semren et al. Validation of the 2nd generation proteasome inhibitor oprozomib for local therapy of pulmonary fibrosis
Rao et al. CBP/P300 Inhibitors mitigate radiation-induced GI syndrome by promoting intestinal stem cell-mediated crypt regeneration
Takeuchi et al. Kruppel-like factor 4 upregulates matrix metalloproteinase 13 expression in chondrocytes via mRNA stabilization
Liu et al. Interleukin-22 inhibits cardiac fibrosis by regulating fibroblast metabolic reprogramming in myocardial infarction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200217